References
- Akazawa, Y., & Nakao, K. (2018). To die or not to die: death
signaling in nonalcoholic fatty liver disease. Journal of
Gastroenterology, 53, 893 - 906.
https://doi.org/10.1007/s00535-018-1451-5.
- Bq, S. (2021). Use of Silimarin in the Treatment of Non-Alcoholic
Fatty Liver Disease (Nafld). Academic Journal of Gastroenterology &
Hepatology. https://doi.org/10.33552/ajgh.2021.03.000552.
- Starley, B., Calcagno, C., & Harrison, S. (2010). Nonalcoholic fatty
liver disease and hepatocellular carcinoma: A weighty connection.
Hepatology, 51. https://doi.org/10.1002/hep.23594.
- Kim, K., & Lee, M. (2018). Pathogenesis of Nonalcoholic
Steatohepatitis and Hormone-Based Therapeutic Approaches. Frontiers in
Endocrinology, 9. https://doi.org/10.3389/fendo.2018.00485.
- Sumida, Y., & Yoneda, M. (2017). Current and future pharmacological
therapies for NAFLD/NASH. Journal of Gastroenterology, 53, 362 - 376.
https://doi.org/10.1007/s00535-017-1415-1.
- LI, Huating et al. Fibroblast growth factor 21 levels are
increased in nonalcoholic fatty liver disease patients and are
correlated with hepatic triglyceride. Journal of Hepatology, v. 53, n.
5, p. 934-940, nov. 2010. Disponível em:
https://doi.org/10.1016/j.jhep.2010.05.018
- XU, P. et al. Fibroblast growth factor 21 attenuates hepatic
fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways.
Toxicology and applied pharmacology, v. 290, p. 43–53, 2016.
- TILLMAN, E. J.; ROLPH, T. FGF21: An Emerging Therapeutic Target for
Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Frontiers in Endocrinology, v. 11, 14 dez. 2020.
- ANA RAIMUNDA DÂMASO et al. Effects of an interdisciplinary weight loss
program on fibroblast growth factor 21 and inflammatory biomarkers in
women with overweight and obesity. Archives of Endocrinology and
Metabolism, 11 nov. 2021.
- Loomba, R., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B. A.,
Goodman, Z. D., Harrison, S. A., Lawitz, E. J., Gunn, N., Imajo, K.,
Ravendhran, N., Akahane, T., Boone, B., Yamaguchi, M., Chatterjee, A.,
Tirucherai, G. S., Shevell, D. E., Du, S., Charles, E. D., &
Abdelmalek, M. F. (2024). Pegbelfermin in Patients With Nonalcoholic
Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b
Study. Clinical gastroenterology and hepatology : the official
clinical practice journal of the American Gastroenterological
Association, 22(1), 102–112.e9.
https://doi.org/10.1016/j.cgh.2023.04.011
- Abdelmalek, M. F., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B.
A., Goodman, Z. D., Lawitz, E. J., Harrison, S. A., Jacobson, I. M.,
Imajo, K., Gunn, N., Halegoua-DeMarzio, D., Akahane, T., Boone, B.,
Yamaguchi, M., Chatterjee, A., Tirucherai, G. S., Shevell, D. E., Du,
S., Charles, E. D., & Loomba, R. (2024). Pegbelfermin in Patients
With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON
2): A Randomized Phase 2b Study. Clinical gastroenterology and
hepatology : the official clinical practice journal of the American
Gastroenterological Association, 22(1), 113–123.e9.
https://doi.org/10.1016/j.cgh.2023.04.012
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I,
Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S,
Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T,
McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K,
White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing
risk of bias in randomised trials. BMJ 2019; 366: l4898.
- Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an
updated guideline for reporting systematic reviews. BMJ 2021;372:71.
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA
(editors). Cochrane Handbook for Systematic Reviews of
Interventions version 6.3 (updated February 2022). Cochrane, 2022.
Available from
www.training.cochrane.org/handbook.
- Harrison, S. A., Ruane, P. J., Freilich, B. L., Neff, G., Patil, R.,
Behling, C. A., Hu, C., Fong, E., de Temple, B., Tillman, E. J.,
Rolph, T. P., Cheng, A., & Yale, K. (2021). Efruxifermin in
non-alcoholic steatohepatitis: a randomized, double-blind,
placebo-controlled, phase 2a trial. Nature medicine, 27(7),
1262–1271. https://doi.org/10.1038/s41591-021-01425-3
- Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R.,
Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E.,
Tillman, E. J., Rolph, T., Cheng, A., & Yale, K. (2022). A
randomized, double-blind, placebo-controlled phase IIa trial of
efruxifermin for patients with compensated NASH cirrhosis. JHEP
reports : innovation in hepatology, 5(1), 100563.
https://doi.org/10.1016/j.jhepr.2022.100563
- Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J.,
Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., Shao,
L., Chan, D., Fong, E., de Temple, B., Shringarpure, R., Tillman, E.
J., Rolph, T., Cheng, A., Yale, K., & HARMONY Study Group (2023).
Safety and efficacy of once-weekly efruxifermin versus placebo in
non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised,
double-blind, placebo-controlled, phase 2b trial. The lancet.
Gastroenterology & hepatology, 8(12), 1080–1093.
https://doi.org/10.1016/S2468-1253(23)00272-8
- Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N.,
Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R.,
Gottwald, M. D., Feng, S., Agollah, G. D., Hartsfield, C. L.,
Mansbach, H., Margalit, M., & Abdelmalek, M. F. (2023). Randomized,
Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. The New
England journal of medicine, 389(11), 998–1008.
https://doi.org/10.1056/NEJMoa2304286
- Loomba, R., Lawitz, E. J., Frias, J. P., Ortiz-Lasanta, G., Johansson,
L., Franey, B. B., Morrow, L., Rosenstock, M., Hartsfield, C. L.,
Chen, C. Y., Tseng, L., Charlton, R. W., Mansbach, H., & Margalit, M.
(2023). Safety, pharmacokinetics, and pharmacodynamics of pegozafermin
in patients with non-alcoholic steatohepatitis: a randomised,
double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose
study. The lancet. Gastroenterology & hepatology, 8(2), 120–132.
https://doi.org/10.1016/S2468-1253(22)00347-8
- Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R.,
Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio,
D., Kundu, S., Noviello, S., Luo, Y., & Christian, R. (2019).
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21
analogue, in patients with non-alcoholic steatohepatitis: a
randomised, double-blind, placebo-controlled, phase 2a trial. Lancet
(London, England), 392(10165), 2705–2717.
https://doi.org/10.1016/S0140-6736(18)31785-9
- Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver
disease (NAFLD): a review of pathophysiology, clinical management and
effects of weight loss. BMC Endocr Disord 2022;22:63.
- Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis.
Gastroenterology 2016; 150:1769.
- Lee
Y, Doumouras AG, Yu J, et al. Complete Resolution of Nonalcoholic
Fatty Liver Disease After Bariatric Surgery: A Systematic Review and
Meta-analysis. Clin Gastroenterol Hepatol 2019; 17:1040.
- Shroff H, VanWagner LB. Cardiovascular disease in nonalcoholic
steatohepatitis: screening and management. Curr Hepatol Rep 2020; 19:
315–26.
- Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease
Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol
2015; 13:2062.
- Verrastro O, Panunzi S, Castagneto-Gissey L, et al.
Bariatric-metabolic surgery versus lifestyle intervention plus best
medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre,
open-label, randomised trial. Lancet 2023; 401:1786.
- Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo
lipogenesis is a distinct characteristic of individuals with
nonalcoholic fatty liver disease. Gastroenterology 2014; 146: 726–35.
- Romero-Gómez M, Lawitz E, Shankar RR, et al. A phase 2a
active-comparator-controlled study to evaluate the efficacy and safety
of efinopegdutide in patients with nonalcoholic fatty liver disease. J
Hepatol 2023; published online June 22. https://doi.org/10.1016/
j.jhep.2023.05.013.
- Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab is
ineffective for patients with bridging fibrosis or compensated
cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterol
2018;155:1140–1153.
- Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with
bridging fibrosis or compensated cirrhosis due to NASH: results from
randomized phase III STELLAR trials. J Hepatol 2020;73:26–39.
- Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of
advanced fibrosis due to nonalcoholic steatohepatitis: data from the
simtuzumab trials. Hepatology 2019;70:1913–1927.
- Cusi K, Isaacs S, Barb D, et al. American Association of Clinical
Endocrinology Clinical Practice Guideline for the Diagnosis and
Management of Nonalcoholic Fatty Liver Disease in Primary Care and
Endocrinology Clinical Settings: Co-Sponsored by the American
Association for the Study of Liver Diseases (AASLD). Endocr Pract
2022; 28:528.
- European Association for the Study of the Liver (EASL), European
Association for the Study of Diabetes (EASD), European Association for
the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice
Guidelines for the management of non-alcoholic fatty liver disease. J
Hepatol 2016; 64:1388.
- Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for
Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2
Diabetes Mellitus: A Randomized Trial. Ann Intern Med 2016; 165:305.
- Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice
Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver
Disease in Children: Recommendations from the Expert Committee on
NAFLD (ECON) and the North American Society of Pediatric
Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr
Gastroenterol Nutr 2017; 64:319.
- Rinella
ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance
on the clinical assessment and management of nonalcoholic fatty liver
disease. Hepatology 2023; 77:1797.
- Cusi
K. Incretin-Based Therapies for the Management of Nonalcoholic Fatty
Liver Disease in Patients With Type 2 Diabetes. Hepatology 2019;
69:2318.
- Ferguson, D., & Finck, B. N. (2021). Emerging therapeutic approaches
for the treatment of NAFLD and type 2 diabetes mellitus. Nature
reviews. Endocrinology, 17(8), 484–495.
- Newsome
PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of
Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med
2021; 384:1113.
- Rader, D. J., Maratos-Flier, E., Nguyen, A., Hom, D., Ferriere, M.,
Li, Y., Kompa, J., Martic, M., Hinder, M., Basson, C. T., Yowe, D.,
Diener, J., Goldfine, A. B., & CLLF580X2102 Study Team (2022).
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in
Obese Adults With Modest Hypertriglyceridemia.
- Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., 3rd, Wasilewska,
K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L.,
Hartsfield, C. L., Agollah, G. D., Mansbach, H., Kastelein, J. J. P.,
& ENTRIGUE Principal Investigators (2023). The FGF21 analog
pegozafermin in severe hypertriglyceridemia: a randomized phase 2
trial. Nature medicine , 29 (7), 1782–1792.
- Huang, Z., Xu, A., & Cheung, B. M. Y. (2017). The Potential Role of
Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension.
Current hypertension reports, 19(4), 28.
- Zarei, M., Pizarro-Delgado, J., Barroso, E., Palomer, X., &
Vázquez-Carrera, M. (2020). Targeting FGF21 for the Treatment of
Nonalcoholic Steatohepatitis. Trends in pharmacological
sciences , 41 (3), 199–208.
- Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., 3rd, Wasilewska,
K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L.,
Hartsfield, C. L., Agollah, G. D., Mansbach, H., Kastelein, J. J. P.,
& ENTRIGUE Principal Investigators (2023). The FGF21 analog
pegozafermin in severe hypertriglyceridemia: a randomized phase 2
trial. Nature medicine, 29(7), 1782–1792.